A personalized, multiomics approach identifies genes involved in cardiac hypertrophy and heart failure. by Santolini, Marc et al.
UCLA
UCLA Previously Published Works
Title
A personalized, multiomics approach identifies genes involved in cardiac hypertrophy 
and heart failure.
Permalink
https://escholarship.org/uc/item/0h76d9hd
Journal
NPJ systems biology and applications, 4(1)
ISSN
2056-7189
Authors
Santolini, Marc
Romay, Milagros C
Yukhtman, Clara L
et al.
Publication Date
2018
DOI
10.1038/s41540-018-0046-3
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ARTICLE OPEN
A personalized, multiomics approach identifies genes involved
in cardiac hypertrophy and heart failure
Marc Santolini1,2,3,4, Milagros C. Romay5, Clara L. Yukhtman6, Christoph D. Rau5,7, Shuxun Ren7, Jeffrey J. Saucerman8, Jessica J. Wang7,
James N. Weiss7, Yibin Wang7, Aldons J. Lusis7,9 and Alain Karma1
A traditional approach to investigate the genetic basis of complex diseases is to identify genes with a global change in expression
between diseased and healthy individuals. However, population heterogeneity may undermine the effort to uncover genes with
significant but individual contribution to the spectrum of disease phenotypes within a population. Here we investigate individual
changes of gene expression when inducing hypertrophy and heart failure in 100+ strains of genetically distinct mice from the
Hybrid Mouse Diversity Panel (HMDP). We find that genes whose expression fold-change correlates in a statistically significant way
with the severity of the disease are either up or down-regulated across strains, and therefore missed by a traditional population-
wide analysis of differential gene expression. Furthermore, those “fold-change” genes are enriched in human cardiac disease genes
and form a dense co-regulated module strongly interacting with the cardiac hypertrophic signaling network in the human
interactome. We validate our approach by showing that the knockdown of Hes1, predicted as a strong candidate, induces a
dramatic reduction of hypertrophy by 80–90% in neonatal rat ventricular myocytes. Our results demonstrate that individualized
approaches are crucial to identify genes underlying complex diseases as well as to develop personalized therapies.
npj Systems Biology and Applications (2018)4:12; doi:10.1038/s41540-018-0046-3
INTRODUCTION
Contrary to “Mendelian” diseases where causality can be traced
back to strong effects of a single gene, common diseases result
from modest effects of many interacting genes.1 Understanding
which genes are involved and how they affect diseases is a major
challenge for designing appropriate therapies.
Heart failure (HF) is a well-studied example of a genetically
complex disease involving multiple processes that eventually lead
to a common phenotype of abnormal ventricular function and
cardiac hypertrophy.2 Numerous studies have attempted to
pinpoint differentially expressed genes (DEGs) to find biomarkers
for the prognosis of the disease and the design of appropriate
drugs,3 as well as explore underlying affected signaling pathways.4
Such studies typically compare the average gene expression
between samples in healthy and diseased states, such as non-
failing vs failing hearts in murine,5 canine,6 or human samples
(see7 for a broad review). Genes are ranked by the strength of
their differential expression, and top ranking genes are further
investigated for pathway enrichment and biomarker potential.
However, because of the different genetic backgrounds of the
surveyed individuals, as well as different severities of HF, those
studies show very limited overlap of DEGs. While separate studies
typically identify tens to hundreds of DEGs, not a single DEG is
common to all studies.7 Moreover, it is unclear whether the
healthy state is itself a well-defined unique state. In particular,
several studies have shown that, due to compensatory mechan-
isms involved in homeostasis, different combinations of ion
channel conductances in neurons and cardiac cells can lead to a
normal electrophysiological phenotype, e.g., a similar bursting
pattern of motor neurons or a similar cardiac action potential and
calcium transient.8,9 This has led to the concept that genetically
distinct individuals represent different “Good Enough Solutions”
corresponding to distinct gene expression patterns underlying a
healthy phenotype. Different combinations of gene expression in
a healthy state resulting from genetic variations would be
expected to yield different DEGs in a diseased state. Thus, small
numbers of DEGs that are only shared by a subset of individuals,
and would be missed by a standard population-wide DEG analysis,
could in principle have a causal role. Identifying these genes
remains a central challenge in personalized medicine.10,11
In order to explore the variability of individual trajectories
leading to hypertrophy and HF, we leverage the Hybrid Mouse
Diversity Panel (HMDP), a model system consisting of >100
genetically diverse strains of mice that we described pre-
viously12,13 (see Methods). Gene expression and phenotypic data
are acquired before and 3 weeks after implantation of a pump
delivering isoproterenol (ISO). This pathological stressor induces a
global response characterized mainly by cardiac hypertrophy
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along with more marginal changes in chamber dilation and
contractile function at the population level.12 As a result, we
primarily focus on the identification of genes relevant for cardiac
hypertrophy. Expression data is collected at the whole heart level
and the Total Heart Weight is used to quantify the degree of
cardiac hypertrophy. Importantly, the severity of the hypertrophic
response is highly variable among strains, ranging from almost no
hypertrophy to up to an 80% increase of heart mass. Our study is
directed at understanding why certain individuals are more
susceptible to or protected against cardiac hypertrophy due to
their genetic backgrounds. Because mice from the same strains
are isogenic and renewable, the HMDP offers the possibility to
analyze differential gene expression and phenotype change in a
unique setting where subjects in the control population can be
matched to a subject with the same genetic background in the
treated population. In that setup, one can correlate the stressor-
related gene expression change with the corresponding pheno-
type change (in our case, heart mass increase) while controlling for
genetic background, thereby disentangling intra-strain (stressor-
induced) and inter-strain (genetics-induced) variations. In the
specific case of HF onto which we focus here, such data could not
be obtained in human studies where heart tissue biopsies are
extracted from either healthy donor hearts or explanted hearts of
late stage HF patients in a genetically diverse population.14 One
would indeed require a population of identical twins in which one
twin for each pair of twins is a heart donor and the other twin is a
late stage HF patient. As such, gene expression data obtained
from those biopsies can only be used to perform a population-
level differential gene expression analysis. In contrast, here we
identify relevant genes by correlating strain-specific temporal
changes of gene expression, i.e., differential expression between a
post-ISO mouse and another pre-ISO mouse from the same strain,
with the corresponding strain-specific changes of phenotype, i.e.,
ratio of heart mass between the post- and pre-ISO mice of the
same strain.
Concretely (see Methods), we calculate the Pearson coefficient
of correlation Cj between the strain-specific fold-change of
expression of gene j among N different strains
Fj ¼ log2
E01 jð Þ
E1 jð Þ ; log2
E02 jð Þ
E2 jð Þ ; ¼ ; log2
E0N jð Þ
EN jð Þ
 
(1)
where Ei jð Þ and E0i jð Þ are the expression levels of gene j for two
isogenic mice of the ith strain before and after ISO treatment,
respectively, and the strain-specific fold-change of heart mass
among different strains
Fm ¼ log2
m01
m1
; log2
m02
m2
; ¼ ; log2
m0N
mN
 
(2)
wheremi andm0i are the total heart mass of isogenic mice of the
ith strain before and after ISO treatment, respectively; we use log2
of expression fold-change to normalize microarrary data and log2
of heart mass fold-change for consistency (Methods). This
correlation method of differential gene expression analysis
identifies a set of DEGs, referred to hereafter as “fold-change”
(FC) genes, for which the absolute value of Cj is above a threshold
of statistical significance determined by randomization of the data
as detailed further in the article and the Methods. The ability to
study a large number (N  100) of strains using the HMDP is
essential to have enough statistical power to establish such a
correlation, a power that has been lacking from previous studies
limited to small numbers of strains.15–18 Moreover, the correlation
coefficients Cj cannot be calculated in the setting of traditional
clinical studies since the fold change of gene expression or heart
mass of subjects with different genetic background is mean-
ingless. Conversely, it is possible to analyze the HMDP data set
using the same type of population-level differential gene
expression analysis used in clinical studies, such as SAM
(Significance Analysis of Microarrays).19 Applied to the HMDP
data set, a method like SAM identifies a gene j as differentially
expressed if the expression data in the control population
log2E1 jð Þ; log2 E2 jð Þ; ¼ ; log2 EN jð Þð Þ and the treated population
log2 E
0
1 jð Þ; log2 E02 jð Þ; ¼ ; log2E0N jð Þ
 
have statistically distin-
guishable mean values, irrespective of the individual reaction to
the stressor Fm. As further detailed in the methods, SAM genes do
not consider the strength of phenotypic change Fm but rely on the
average gene expression change hFji, while FC genes consider
both expression and phenotypic changes through an interaction
term hFjFmi:
Based on our computation of the Cj correlation coefficients, we
find a small set of 36 FC genes and compare them to a larger set
of genes identified with SAM (referred to hereafter as SAM genes).
Interestingly, the sets of FC and SAM genes have negligible
overlap. The FC genes are not identified as significantly changed
at the population level because they typically have opposite fold
changes in low and high hypertrophy strains that cancel each
other when averaged over all strains in the population-wide case.
We show that the FC genes are strongly enriched in cardiac
disease genes from previous Genome-Wide Association Studies
(GWAS), while SAM genes are in contrary enriched in fibrosis
genes. We then show that those two sets form two distinct
communities in the co-expression network among healthy as well
as ISO-injected strains and we identify potential transcription
factors (TFs) to explain the observed co-regulation of FC genes.
Moreover, we find that the proteins encoded by the FC genes, but
not the SAM genes, interact predominantly with proteins
belonging to a cardiac hypertrophic signaling network (CHSN)
that has been shown to provide a predictive model of
hypertrophy in relation to multiple stressors including ISO.20
Interestingly, we find that one of the FC genes, namely Hes1, is
also a predicted TF and an important interactor with the CHSN.
Using a knockdown approach, we find that it plays a major role in
cardiac hypertrophy, allowing us to validate our personalized,
multiomics approach.
RESULTS
Two types of responses to stressor-induced cardiac hypertrophy
and heart failure
We begin with an example showing two distinct ways to describe
the response to ISO in the HMDP (see Fig. 1 and Methods). First,
one can note that ISO induces a global response across all strains,
resulting in cardiac hypertrophy. This is seen in Fig. 1a, where the
distribution of heart mass among the post-ISO strains can clearly
be distinguished from the pre-ISO distribution (p < 2.2e-16 under
Student t-test). At the gene level, such a response is typically
analyzed by looking for DEGs at the population level, i.e., genes for
which the change in average expression with the stressor is
significantly greater than the variability with and without the
stressor (Fig. 1b). Typical tools include t-test,21 SAM,19 or LIMMA.22
Genes found with these methods have a differential expression
profile at the population level and are therefore potential
biomarkers of the trait of interest (see microarray data for
Serpina3n, an example high-ranking SAM gene, in Fig. 1c).
However, despite the global response in the level of gene
expression to ISO, the degree of hypertrophy among individual
strains is highly variable, from almost none to an 80% increase of
heart weight (Fig. 1d). This calls for an evaluation of the strength
of differential gene expression at the individual level. In particular,
a whole new class of genes becomes available for analysis. Indeed,
even if a gene does not show population-wide average differential
expression, it can show extensive variation at the individual, strain-
specific level (Fig. 1e). This is the case for the gene Kcnip2
encoding the protein KChIP2, which interacts with pore forming
subunits (Kv4.2 and Kv4.3) of the transient outward current Ito
A personalized, multiomics approach...
M Santolini et al.
2
npj Systems Biology and Applications (2018) 12 Published in partnership with the Systems Biology Institute
1
2
3
4
5
6
7
8
9
0
()
:,;
expressed in heart, and which has been implicated in cardiac
hypertrophy.23–25 Though not showing population-wide differen-
tial expression (Fig. 1f), its individual fold-change of expression can
vary drastically from 2-fold decrease to a 2-fold increase
depending on the considered strain (Fig. 1g). Interestingly, when
comparing the individual variations of those two types of genes
with the degree of hypertrophy (Fig. 1h, i, k), one can see that
global DEGs are not necessarily good descriptors of the individual
changes of phenotype (Fig. 1j), unlike the second type of genes
missed by a traditional population-wide method (Fig. 1l). In
particular, in the case of Kcnip2, we observe a significant positive
correlation with the severity of hypertrophy (r= 0.4, p= 1.5e-4).
A personalized, multiomics approach...
M Santolini et al.
3
Published in partnership with the Systems Biology Institute npj Systems Biology and Applications (2018) 12
This is particularly interesting since Kcnip2 has previously been
shown to be down-regulated during cardiac hypertrophy24,26 in
the strain 129 × 1/SvJ. While we confirm this finding, we also
observe that it is unusual in a broader context, and that Kcnip2 is
most of the time up-regulated in strains with marked hypertrophy.
In the following, we generalize these observations to identify a
larger set of genes that, like Kcnip2, have an individual FC
correlated to the severity of hypertrophy, and we compare this set
to the complete set of DEGs identified by the population-level
SAM method.
Identification of genes associated with the severity of hypertrophy
Here we develop a method to determine which genes show
individual, strain-specific expression FCs significantly correlated to
the individual hypertrophic response measured by the individual
fold-change of heart mass. We use microarray and phenotype
expression data described in.13 Since our methodology is based
on correlations, we choose to select those genes that belong to
the giant component of the gene co-expression network above a
certain correlation cutoff (see Methods and Figs. S1, 2). The
advantages of such a filter compared to one based on absolute
expression levels is that it yields a clear, well-defined cutoff (Figure
S1b) while also rejecting genes having high expression but
artefactual correlations (e.g., hitting the microarray saturation level
in Figure S1c). We obtain a filtered set of 11,279 high-confidence
genes. We then compute for all genes the absolute Pearson
correlation between the gene expression fold-change and the
individual hypertrophic response (Fig. 2a, blue histogram). To
control for False Positives, we compute the expected correlations
when randomizing the phenotype by shuffling strain labels (see
Methods and Fig. 2a, red histogram). One can see significant
enrichment in genes with high correlation to the trait. To quantify
this enrichment, we compute the proportion of observed (blue)
correlations divided by the proportion of correlations in the
randomized cases (red) above various correlation cutoffs. Figure
2b shows this enrichment as a function of the gene rank, ordered
by decreasing absolute value of the correlation with hypertrophy.
The enrichment shows a peak at 36 genes, followed by a plateau
until ~500 genes, and a subsequent decrease. We define these 36
genes as our candidates to describe the hypertrophic spectrum.
These genes are listed in Table 1, along with references supporting
the involvement of several of them in cardiac hypertrophy and HF.
In the following, we refer to this set of genes as the “FC” set.
As a comparison, we compute the population-wide DEGs using
Significance Analysis of Microarray or SAM.19 This exhibits 2538
DEGs at a False Discovery Rate of 1e-3 (see Methods). Interestingly,
we find no significant overlap (p= 0.68, hypergeometric test)
between these SAM genes and the FC set, with six genes common
to both sets (Tspan17, Ppp1r9a, Bclaf1, AW549877, Gss,
2310022B05Rik, and 9430041O17Rikm). In general, correlations
between the individual fold-changes of the SAM genes and the
degree of hypertrophy are found to be quite low (Fig. 2c). This
shows that population-wide analyses do not naturally yield genes
associated to the individual strength of phenotypic change, calling
for a specific method to uncover them.
The 36 FC genes are shown in Fig. 2d. As expected from the
absence of overlap with SAM genes, the FC genes have both
negative (blue) and positive (red) fold-change across the different
strains, meaning that they have negligible average fold-change at
the population level. A question that arises is whether the
variability observed in the individual fold-changes of gene
expression across strains is a consequence of genetic variability,
or merely reflects environmental or experimental spurious effects.
To investigate this question, we take advantage of the fact that
gene expression has been replicated in nine strains post-ISO. Since
mice from the same strain have a similar genetic background, they
should therefore show very comparable individual fold-changes.
Expression fold-change is shown for the 36 FC genes for the
replicated strains in Figure S3a. We assess the replicability by
computing the Spearman rank correlation of the 36 FC genes fold-
change profiles between mice from replicated strains. We find a
large mean correlation of 0.76, compared to 0.14 for pairs of
strains taken at random among the non-replicated pool with a
statistically very significant p-value (p= 1.6e-7, Wilcoxon test, see
Figure S3b). This result shows that individual fold-changes are
tightly controlled at the genetic level and that the ranking of the
genes by FC is preserved for approximately 2/3 of the cases. We
also assessed replicability by making a scatter plot of the log2
expression fold-change computed with the original and replicated
ISO treated hearts compared to the same control heart for the 36
FC genes and 9 strains (Figure S3c). A correlation analysis of this
scatter plot yields a correlation of 0.57 and very low p-value (p <
2.2e-16), confirming that individual fold-changes are predomi-
nantly genetically determined.
In the following, we wish to evaluate further the biological
signal carried by these FC genes missed by population-wide
methods.
Biological relevance of the identified FC genes
Given the importance of the genetic control of those genes, they
must be more susceptible to genetic variations. To explore that
idea, we look at the enrichment in disease genes coming from
previous GWAS. We use HuGE database of human genes
associated with 2711 different diseases (see Methods). First, we
convert the mouse gene names to human as described in the
Methods. Then, we rank the diseases according to their
enrichment in 36 FC (resp. 36 best SAM) genes using a
hypergeometric test assuming as null hypothesis a uniform
repartition of the genes across diseases. Results are shown in
Figs. 2e, f for the 15 most enriched diseases in each case. We
observe that FC genes are strongly enriched in heart diseases (11
in the 15 most enriched diseases) while SAM genes are only
Fig. 1 Two types of responses to stressor-induced heart failure. a Histograms of the pre-ISO (blue) and post-ISO (red) heart masses of the
HMDP strains. b Typical Differentially Expressed Genes (DEGs) show clear population-average fold-change allowing distinguishing the two
populations of strains. c An example of such strong DEG, namely Serpina3n. d Histogram of the heart mass fold-change (FC) computed for
each strain from the HMDP. e Expression FC at the individual level can lead to cases were the population-average FC is null while the
individual FCs are not. f Kcnip2 is a good example of a gene with no population-wide average FC. g However, at the individual level, Kcnip2
shows strong variations, as seen in the histogram of individual FCs at the strain level (log2 of post over pre-ISO expression ratio). In particular,
some strains have a 4-fold decrease of expression (−2 in log2), while others have a 4-fold increase (+2). h For better visualization, the strain-
specific heart mass FC is shown by decreasing strength. Red bars indicate increase and blue bars decrease in value. i Serpina3n log FC is shown
with the same strain ordering than in (h). Its population-wide FC is high (3.9), with most strains showing a strong positive FC (red bars). j
However, the correlation of Serpina3n FC with the heart mass FC is not significant (r=−0.09, p= 0.43). k On the other hand, Kcnip2 shows a
weak population-wide FC (FC= 0.85). In particular, some strains show an increased expression (red bars) while others show a decreased
expression (blue bars). The red arrow indicates the 129 × 1/SvJ strain in which Kcnip2 has previously been shown to be down-regulated during
cardiac hypertrophy.24 l Contrary to Serpina3n, Kcnip2 FC is significantly correlated to heart mass FC (r= 0.4, p= 1.5e-4), with increased
expression corresponding to high hypertrophy and decreased expression corresponding to low hypertrophy
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enriched in two cardiac diseases and in fibrosis, a feature
characteristic of the structural remodeling taking place during
HF.27 Those findings exhibit two distinct roles of FC and SAM
genes in the progression of cardiac hypertrophy. While the cross-
talk between cardiac fibroblasts and myocytes during cardiac
hypertrophy has been studied previously,28 here we disentangle
their relative contributions into a shared, population-wide
fibroblastic component, and a fine-tuned, individualized compo-
nent capable of explaining the severity of cardiac hypertrophy.
Moreover, the enrichment of FC genes in human GWAS genes also
highlights the relevance of the present HMDP data analysis to
human cardiac hypertrophy and HF.
Co-expression and co-regulation
The identified sets of population-level and individual FC genes
have until now been considered as collections of independent
genes. However, in the cell, genes function together to achieve
higher-order physiological functions. Such a collective behavior
can be assessed in the framework of co-expression networks,
where genes are related by the similarity of their profile of
expression across different conditions. In the context of the HMDP,
we investigate whether the predicted sets of genes show
evidence of co-regulation in healthy and post-ISO hypertrophic
strains. To that extent, we compute the squared Pearson
correlations (r2) between the 36 best genes of both the FC and
SAM sets. Correlation matrices are then cut off at r2 > 0.1 to keep
significant interactions. We show in Fig. 3a and b the resulting co-
expression networks in pre and post-ISO conditions. We clearly
see that the two sets of genes form dense modules, and are
disconnected from each other, with only few links between the
two sets. Interestingly, we see that the biomarker and modulator
of hypertrophy Nppb29 acts as a bridge between the two modules
in pre-ISO condition (Fig. 3a, top), and is even found strongly co-
expressed with the SAM genes in post-ISO mice (Fig. 3b). This
suggests a role for Nppb in driving a cross-talk between FC genes
and SAM genes. Finally, to quantify the relative density of the
modules, we compared them to 1000 sets of a similar number of
randomly selected genes. We show the resulting Z scores in Fig.
3c. Both SAM and FC sets show much stronger co-expression than
randomly expected, with the SAM module being even denser
under ISO condition. On the contrary, the density of links between
the two modules is significantly smaller than expected by chance,
indicating that the two sets of genes are disjoint sets in the co-
expression network. Overall, these results show that the FC and
SAM genes form two tight, disjoint communities in the co-
expression network, both in pre-ISO and post-ISO mice.
The finding that the FC genes are strongly co-expressed
suggests that they are co-regulated. To explore this possibility,
we look for enrichment in common TF binding sites in the vicinity
of the 36 FC genes. To compute the enrichment, we use iRegulon,
a recent algorithm integrating different TF motifs databases and
using phylogenic conservation to identify overrepresented bind-
ing sites in the −20/ +20 kb regions around the Transcription Start
Sites of genes of interest (see Methods).30 The identified motifs are
then ranked by target enrichment among selected genes, and are
associated with a list of putative TFs that can bind them (Fig. 3c).
We find that the best-ranked motif is associated with repressor TFs
Scrt1 and Scrt2, known to modulate the action of basic helix-loop-
helix TFs.31 Interestingly, the corresponding PWM motif is also
matched to Snai3 TF, a gene ranked 3rd among SAM genes. The
2nd motif, VDR, is known to be involved in heart failure and
cardiac hypertrophy.32 Finally, the sixth predicted TF is associated
Fig. 2 Identification of genes associated with the severity of cardiac hypertrophy. a Histogram of the absolute values of the correlations
between the FCs of genes expression and hypertrophy for all genes (blue, observed, red, randomized phenotype). Genes individual FCs are
more correlated to hypertrophy than expected. Inset plot corresponds to the best observed correlation. b The previous enrichment is
assessed by computing the ratio of the area under the observed and randomized curve as a function of correlation cutoffs. Cutoffs are
matched to the genes correlations ranked in decreasing order. The enrichment peaks at N= 36 genes, which defines the set of “FC” genes. c
Boxplot comparing the values of the absolute correlation with hypertrophy for the 2538 SAM genes resulting from a population-wide DEG
study (see main text) and for the 36 identified individual FC genes. FC genes have significantly higher correlation. d Heatmap showing the 36
genes (columns) log fold-changes across strains (rows). The left column shows the degree of hypertrophy (yellow= low, dark blue= high).
Hierarchical clustering shows a natural grouping of the strains by the severity of hypertrophy. e Enrichment of 36 best FC genes in human
disease genes from GWAS studies. The 15 most enriched sets are shown. Red arrows indicate cardiac diseases (11/15). The enrichment of the
36 best SAM genes is shown for comparison, with low enrichment in the found sets. f Similar than (g), for 36 SAM genes. These genes show
enrichment in “Fibrosis”, a feature of structural remodeling during cardiac hypertrophy
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with Hes1, which ranks 10th among the FC genes. This indicates
that there is a cross-talk between the two modules at the gene
regulatory level, with both FC and SAM genes being involved in
the regulation of the expression of the FC genes.
Exploration of the neighborhood in the interactome
While useful to detect gene regulatory changes involved in the
disease process, gene expression does not capture post-
translational changes and interactions that occur at the protein
level. To explore the potential involvement of the predicted sets of
genes at the protein level, we use a previously published human
interactome combining high-throughput and literature curated
protein–protein, metabolic, kinase–substrate, signaling and to a
lesser extent regulatory interactions.33 After converting to human
gene symbols (see Methods), the proteins encoded by the 36 best
FC and SAM genes have respectively 364 and 346 interacting
partners. We then compute pathway enrichment for these
neighbors (see Methods). The other most highly enriched pathway
is linked to NFAT signaling, known to be important in HF.34
Interestingly, we find that the second most enriched pathway for
FC neighbors is a previously published Cardiac Hypertrophy
Signaling Network (CHSN) containing 106 nodes (corresponding
to 218 genes) giving a predictive model of hypertrophy in
response to multiple stressors including ISO20 (Figure S4). Indeed,
about 14% of FC neighbors are components of this network,
compared to a predicted random association of 4% (Z= 4, Fig. 3d).
The CHSN is shown in Fig. 3e and in more details in Figure S5,
along with FC nodes directly interacting with CHSN nodes. In
particular, we find that Hes1 is interacting with several nodes of
the CHSN at different levels of the hierarchy, namely FAK, JAK,
STAT, CamK, PKC, and HDAC.
Experimental validation of Hes1
The previous results point toward a role for Hes1 in cardiac
hypertrophy and heart failure. Indeed, Hes1 was found to be a FC
gene, an upstream regulator of FC genes, and an interactor with
several components of the CHSN. To determine the function of
Hes1 in the context of cardiac hypertrophy and heart failure, we
performed siRNA knockdown in neonatal rat ventricular myocytes
followed by treatment with beta-adrenergic agonist ISO or alpha-
adrenergic agonist phenylephrine (PE) containing media. Both
agents induce hypertrophy through different molecular pathways,
as can be seen in the CHSN (see Fig. 3e). Using siRNA to silence
Hes1 expression, we achieved a 20–40% decrease in Hes1
expression when compared to transfection control (Fig. 4a and
Table S3). At the molecular level, treatment with either ISO or PE
containing media drastically increases the expression of the HF
markers Nppa and Nppb, which rose 3.5 and 7.9-fold, respectively
under ISO treatment and 11-fold and 13-fold, under PE treatment
in cells transfected with the control siRNA. Strikingly, knockdown
of Hes1 expression strongly impaired the induction of these two
markers under both treatment conditions. Nppa induction was
reduced up to 110 and 88% under ISO and PE treatment while
Nppb induction was reduced up to 66 and 91% under ISO and PE
treatment, respectively. In addition to these molecular changes,
we investigated the role of Hes1 in modulating the increase in
cardiomyocyte cell cross-sectional area upon treatment with ISO
and/or PE. As expected, following ISO/PE treatment, cells
transfected with the control siRNA doubled in cellular cross-
sectional area (Fig. 4c, Figure S6, and Table S4). In comparison,
cells transfected with the Hes1 siRNA showed up to 87 and 79%
reduction in cell cross-sectional area increase following treatment
with ISO and PE, respectively. This effect is consistent with the fact
that HMDP strains showing no or mild hypertrophy exhibit strong
negative fold-change of Hes1 (Figure S7). Taken together, these
findings strongly suggest a role for Hes1 as a regulator of cardiac
hypertrophy in vitro.
DISCUSSION
In the present study, we investigated the spectrum of cardiac
hypertrophy and HF development in 100+ genetically diverse
Table 1. List of genes predicted with the individual fold-change
analysis
Rank Gene Correlation Known role from the literature
1 Rffl −0.446656 Hypertension57
2 Wdr1 0.415692 Cardiac Hypertrophy58
3 Nppb 0.408886 Heart failure marker59
4 Atp6v0a1 0.407205 Hypertension60
5 Ankrd1 0.406246 Dilated cardiomyopathy61
6 Eif4a1 0.404824
7 Dtr (HB-EGF) 0.403043 Heart failure62
8 Kcnip2 0.402246 Downregulated in
hypertrophy23,24,26
9 Pcdhgc4 −0.402053
10 Hes1 0.400076 Heart outflow tract
development.63 Validation in the
present study.
11 4930504E06Rik 0.396189
12 Akap9 −0.389713 LQT syndrome64
13 2310022B05Rik 0.3897
14 Bclaf1 −0.388563
15 Ttc13 −0.387981
16 Nipsnap3b 0.387325
17 Gss 0.386407 Glutathione synthetase, linked to
cardiac abnormalities65–67
18 Klhl23 −0.385625
19 Tspan17 0.384865
20 Tnni2 −0.383516
21 Cab39l −0.381902
22 Ptrf (Cavin-1) 0.381134 Dilated cardiomyopathy68
23 Dedd 0.378059
24 9430041O17Rik 0.375683
25 Fgf16 0.373829 Heart disease69
26 Ehd2 0.372787 Regulate cardiac membrane
protein targeting.70 Interact with
ankyrin-B (ANK2 gene whose
mutation is associated with
hypertrophic cardiomyopathy71)
27 Ppp1r9a −0.372641 Subunit of the same complex
than PPP1R3A, involved in HF in
human patients51
28 Kremen 0.372366 Interacts with Wnt signaling72
Wnt signaling also plays a role in
cardiac hypertrophy73
29 Scara5 −0.372294
30 Zfp523 −0.372223
31 Nfatc1 0.371409 Cardiac hypertrophy34
32 Corin −0.369546 Cardiac protease that regulates
blood pressure by activating
natriuretic peptides, involved in
cardiac hypertrophy74
33 Prnpip1 0.369466
34 Lrrc1 0.369161
35 AW549877 −0.368865
36 Mkrn3 −0.368269
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mice from the HMDP when subjected to chronic ISO infusion. We
have analyzed two types of responses. First, the global response at
the population level with a large number (1000+) of genes
involved, as detected by the SAM algorithm. Their global fold-
change is representative of the global hypertrophy observed
across all strains. However, the magnitude of their fold-change at
the individual level does not predict the degree of individual
hypertrophy. Using a correlation-based method, we found another
group of ~40 genes that predicts the degree of hypertrophy. We
named these the “FC” genes in reference of the fact that we found
them using their individual, strain-specific fold-change. Surpris-
ingly, these genes have a near zero fold-change at the population
level due to the canceling contributions of up and down-
regulation in different strains, so that they are not detected using
classical differential expression tools. While several FC genes have
previously been implicated in cardiac hypertrophy and HF (see
A personalized, multiomics approach...
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Table 1), their high variability in such a controlled setup has not
been explored previously. We showed that these genes are
enriched for heart failure gene candidates previously described in
the literature, as well as for human cardiac disease genes. On the
other hand, the best SAM genes are enriched in fibrosis disease
genes. ISO has been shown to induce first myocardial fibrosis
concomitantly with myocyte necrosis, followed by myocyte
hypertrophy on a longer time scale,35 and fibrosis is also known
to be an early manifestation of hypertrophic cardiomyopathy.36
Our results suggest that population-level SAM genes are
predominantly associated with the early fibroblast response. On
the other hand, since the change of heart mass is primarily
determined by myocyte growth, our results suggest that FC genes
are associated with the strain-specific degree of myocyte growth
induced by beta-adrenergic stimulation.
We further investigated the roles of these genes in different
biological networks. We found that both FC and SAM genes form
distinct co-expressed modules. Interestingly, Nppb (encoding the
BNP protein), a widely used biomarker and modulator29 of HF,
belongs to the FC set but is co-expressed with SAM genes in
healthy mice, providing a unique bridge between the two sets. We
note that this result is consistent with the previous finding that
Nppb is an antifibrotic hormone produced by myocytes with an
important role as a local regulator of ventricular remodeling in
mice.37 Indeed, Nppb is correlated to the fibrotic SAM genes in
healthy mice, consistent with a regulatory homeostatic behavior,
but is found among FC genes after beta-adrenergic stimulation,
consistent with a response proportionate to myocytes hypertro-
phy. It is also interesting to note that the SAM module overlaps
significantly (p= 3.4e-6, hypergeometric test) with a co-expression
module previously found in post-ISO mice and shown to be
involved in cardiac hypertrophy.38 Indeed, it shares the genes
Timp1, Tnc, Mfap5, Col14a1 and Adamts2, the latter of which was
validated experimentally as a regulator of cardiac hypertrophy.
We then predicted several TFs to study this co-regulation.
Interestingly, among the top TFs predicted as regulators of the FC
genes, one of them, Hes1, belongs to the FC genes, and another
one, Snai3, belongs to the SAM genes. We note that both
inhibitory (Snai3, Hes1) and activatory (Vdr, Srebf1) TFs were found
to have enriched binding sites around FC genes TSSs. This
suggests a potential regulatory balance that could explain the up
and down-regulation observed for these genes across strains. We
then looked at potential post-translational effects at the protein
level by using an integrated interactome. We found that FC genes
were strongly interacting with a CHSN previously shown to be
predictive of cardiac hypertrophy in response to ISO and other
stressors.20 This may indicate that several of those genes are
upstream of a causal chain of events at the post-translational level
that control myocyte growth. We note that the FC gene Nppb is
present both as an input and an output of the CHSN. This
exemplifies an interesting feedback architecture where down-
stream effects can causally affect upstream regulation. Overall, the
FC genes constitute a HF “disease module” formed of co-regulated
genes connected to the CHSN at the protein level.
A key finding of our study is that there is strong strain-to-strain
variation in response to a stressor under similar well-controlled
environmental conditions. This variation is largely explained by
the different genetic backgrounds, as shown by the consistent
responses in mice from same strains (Figure S3) and the strong
enrichment in heart diseases GWAS (Fig. 2e). For example, Kcnip2
is known to be downregulated concomitantly with a reduction of
Ito magnitude in cardiac hypertrophy.
24,26 Our results are
consistent with this finding for the previously studied 129 × 1/
SvJ strain,24 but show that Kcnip2 is upregulated in many strains
with pronounced hypertrophy leading to an overall positive
correlation between Kcnip2 expression and heart mass FC. This
indicates that there are multiple possible compensatory mechan-
isms underlying a similar patho-phenotype. Similarly, we observed
strong variation in the fold-change of Nppb. It was previously
shown to be over-expressed during cardiac hypertrophy as an
anti-fibrotic factor.29 Using our multiple strains setup, we observed
a positive correlation between Nppb change of expression and the
degree of hypertrophy. However, we also observed some cases
were hypertrophic strains exhibit down-regulation of Nppb,
including the widely used C57BL/6 J and 129 × 1/SvJ strains (see
Fig. 2d and S3).
Finally, our approach was validated by testing Hes1’s role in
cardiac hypertrophy. Hes1 was chosen because of its involvement
at different levels: found as a FC gene, Hes1 is also a predicted TF
regulating the FC genes and a key interactor of the CHSN. Hes1 is
part of the Notch signaling pathway which is highly conserved
and involved in cell-cell communication between adjacent cells.39
This pathway is well known to play a crucial role in cardiac
development and disease. Notch activity is required in complex
organs like the heart that necessitate the coordinated develop-
ment of multiple parts.40 Specifically, functional studies have
shown that Notch activity is required for cardiovascular develop-
ment and that Notch signaling causes downstream effects such as
cell fate specification, cell proliferation, progenitor cell mainte-
nance, apoptosis, and boundary formation.39 In previous studies,
Hes1 expression was observed to increase following myocardial
infarction and other ischemic cardiomyopathies. Increased expres-
sion of Hes1 was also shown to inhibit apoptosis of cardiomyo-
cytes and promote instead their viability. However, whether Hes1
acts as a regulator of heart failure markers has remained unclear.41
Here, we show that Hes1 knock-down induces a dramatic
reduction of hypertrophy by 80–90% (Fig. 4c), identifying for the
first time Hes1 as a key regulator of cardiac hypertrophy.
Importantly, this result is consistent with the HMDP, where strains
with no or mild hypertrophy have 20–50% decrease in Hes1 after
ISO injection (Figure S7b).
Overall, we have explored the individual, strain-specific
responses to stressor-induced HF and identify 36 FC genes that
are missed by traditional population-wide methods of DEG
Fig. 3 FC genes are co-regulated and significantly connected to the cardiac hypertrophy signaling network (CHSN). a Co-expression networks
of the 36 best FC and SAM genes in healthy and post-ISO hypertrophic strains. Edges are drawn between two genes if the square Pearson
correlation is greater than 0.1 (r2 > 0.1). The two modules segregate naturally using a force layout algorithm, showing that the modules have
high clustering but only few links between themselves. Interestingly, Nppb (purple arrow) segregates with SAM genes, especially in ISO
condition. b The edge density of the FC module, the SAM module, and the FC to SAM edges is computed and compared to the density
expected for random sets of nodes of the same size (see Methods). The corresponding Z scores are significantly high (Z > 2) for both modules,
indicating high co-expression. However, there are significantly fewer links than expected between the two modules (Z <−2), indicating that
they are disjoint in the co-expression network, (c) List of the 6 most enriched TF motifs in the ±20 kb regions around the 36 FC genes TSSs
predicted using iRegulon.30 Interestingly, Snai3 (blue arrow) is a SAM gene and Hes1 (red arrow) a FC gene, suggesting a crosstalk between
the two modules at the gene regulatory level. d Proportion of neighbors in the interactome that belong to the Cardiac Hypertrophy Signaling
Network or CHSN20 for different gene sets: the FC set (red arrow), the 36 best SAM genes (blue arrow) and 1000 realizations of random nodes
in the interactome with the same size as the FC set (gray histogram). Z-scores are computed relative to the gray distribution. The FC set is
significantly connected to the CHSN, while the SAM genes are not significantly different than a random set. e Network visualization of the
CHSN,56 along with neighbors from the 36 best FC genes (red nodes). A more detailed interaction network is shown in Figure S5
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analysis. We have shown that these FC genes provide a
completely distinct, albeit complementary, picture of HF than
population-wide DEGs. In particular, FC genes are enriched in
human cardiac disease genes and hypertrophic pathways. This is
important since previous studies that use population-level
methods to identify DEGs have concluded that murine models
are of limited relevance to human HF.42,43 In contrast, our findings
show that FC genes, identified by a personalized differential
expression analysis in a genetically diverse population of mice, are
relevant to human HF. By linking those genes both to upstream
regulators and to a signaling network predictive of cardiac
hypertrophy, we provide new insights into the regulation of the
severity of and resistance to cardiac hypertrophy at the individual
level, and validate Hes1 as a regulator of cardiac hypertrophy
in vitro. We believe this approach to be critically important for the
appropriate design of upcoming experiments directed at unravel-
ing causal genes in complex diseases.
METHODS
Overview of the HMDP
The HMDP consists of a population of over 100 inbred mouse strains
selected for usage in systematic genetic analyses of complex traits. Strain
were selected to increase resolution of genetic mapping with a renewable
resource that is available to all investigators worldwide as well as to create
a shared data repository that would allow the integration of data across
multiple scales, including genomic, transcriptomic, metabolomic, proteo-
mic, and clinical phenotypes. The core of our panel for association
mapping44–46 consists of 29 classic parental inbred strains which are a
subset of a group of mice commonly called the mouse diversity panel.
HMDP strains were chosen by eliminating closely related strains and
removing wild-derived strains. The decision to remove wild-derived stains
reflects a tradeoff between statistical power and genetic diversity. While
leaving out wild-derived strains sacrifices genetic diversity to some degree,
the HMDP increased the statistical power (assuming the same number of
animals) to identify genetic variants polymorphic among the classical
inbred strains which affect traits. These variants yield a tremendous
amount of phenotypic diversity among the classical inbred strains.
ISO treatment
As previously described,13,47 30 mg per kg body weight per day of ISO was
administered for 21 days in 8–10 week old female mice using ALZET
osmotic mini-pumps, which were surgically implanted intraperitoneally. All
animal experiments were conducted following guidelines established and
approved by the University of California, Los Angeles Institutional Animal
Care and Use Committee (IACUC) and housed in an IACUC-approved
vivarium with daily monitoring by vivarium personnel.
Hypertrophy measurement
As each mouse in a strain is genetically identical, we used several mice
from the same strain for measuring the cardiac hypertrophic response to
ISO treatment. More specifically, we used on average three untreated mice
serving as control hearts and about three ISO treated mice of the same
strain to measure the cardiac hypertrophic response. This response was
studied in a total of 104 genetically different strains with the precise
number of control and treated hearts for each strain given in Table S1. The
number of untreated control hearts per strain was 2.75. The average
number of ISO treated hearts per strain was 3.5. At sacrifice, hearts were
excised, drained of excess blood and weighed. Each of the four chambers
of the heart (left ventricle with inter-ventricular septum, right-ventricular
free wall, right and left atria) was isolated and subsequently weighed.
Cardiac hypertrophy for a given strain was calculated as the increase in
average total heart weight after ISO treatment compared to control mice.
Heart biopsy for microarray analysis
As for the hypertrophy measurement, we exploited the fact that each
mouse in a strain is genetically identical to extract heart tissue for
microarray analysis in both untreated and ISO treated mice from the same
strain. The left ventricle of each heart was cut into quarters with each piece
weighing on average about ±25mg a few mg depending on the amount
of hypertrophy and two pieces were used for microarray data analysis. Due
to the large number of strains analyzed and the cost of microarray data
analysis, we used one untreated control heart and one ISO treated heart
per strain for about 90% of the strains. However, since mice of a given
strain are renewable, the HMPD offers the possibility to use triplets,
quadruplets, and higher multiples of isogenic subjects for experimentation.
This feature was used to measure gene expression in replicates (e.g., two
hearts in control or two hearts after ISO treatment) to test for replicability
in ~10% of the strains (9 strains analyzed in Figure S3).
Microarray data analysis
Following homogenization of left ventricular tissue samples in QIAzol, RNA
was extracted using the Qiagen miRNAeasy extraction kit, and verified as
having a RIN > 7 by Agilent Bioanalyzer. Two RNA samples were pooled for
each strain and experimental condition and arrayed on Illumina Mouse
Reference 8 version 2.0 chips. Analysis was conducted using the Neqc
algorithm included in the limma R package48 and batch effects addressed
Fig. 4 Validation of Hes1 as a cardiac hypertrophy regulator. a Hes1 mRNA expression following 48 h after siRNA transfection in a control,
isoproterenol or phenylephrine medium. Three siRNAs were used, a scrambled, control one and two Hes1 specific siRNAs. Both Hes1 siRNAs
show systematic downregulation of Hes1 mRNA in all conditions. b Effect of Hes1 knockdown on the known hypertrophic makers Nppa and
Nppb. In both case, Hes1 knockdown leads to a significant change in biomarkers activation in isoproterenol and phenylephrine conditions (*p
< 0.05, ***p < 1e-3, Student t-test). c Effect of Hes1 knockdown on neonatal rat ventricular myocytes size relative to control medium cell cross-
sectional area. Both siRNAs lead to a drastic 80–90% decrease in hypertrophy in both isoproterenol and phenylephrine media
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using COMbat.49 In designing our study, we were cautious and distributed
the treated and control conditions evenly across our three batches as well
as endeavoring to include a diverse set of genetic backgrounds in each
batch. Thus, we do not believe that our data suffer from the potential
batch artifacts as reported in.50
Overview of the gene correlation method
Traditional analyses of differential gene expression for complex diseases
rely on gene expression data for two populations: a control population and
a diseased (or drug treated) population. For example, in the case of HF, the
control population consists of N donors with healthy hearts intended to be
used for transplantation, which are biopsied for gene expression analysis
when left unused, and the diseased population consists of M late stage
heart failure patients whose hearts are explanted and then biopsied for
gene expression analysis. Importantly, the subjects in the control and
diseased population are all genetically different. Hence, if we label the
subjects by Si , where the index i refers to subject i with its own genetic
background distinct from all other subjects, the N subjects in the control
population are ðS1; S2; ::::; SNÞ (control subjects) and the M subjects in the
diseased population are ðSNþ1; SNþ2; ::::; SNþMÞ (diseased subjects).
The data sets used for the differential gene expression analysis
consists then of the expression level (log2 mRNA number) of a large
number of K genes for each subject. K is typically in the range of
several thousands, and thus much larger than the number of control
or diseased subjects (N or M, respectively) that are at most a few
hundreds in the most extensive studies to date,51 and only a few
subjects in each population in earlier studies.7 Let us label the expression
levels by EiðjÞ where the subscript i refers to subject i and the index j ¼ 1; K
refers to gene j. To find out if a given gene j among the K genes is
differentially expressed, it suffices to use a standard statistical test
analogous to a student t-test to decide if the gene expression data for
the control group log2 E1 jð Þ; log2 E2 jð Þ; ¼ ; log2 EN jð Þð Þ (expression data
for gene j in control population) and for the diseased group
ðlog2 ENþ1 jð Þ; log2 ENþ2ðjÞ; ¼ ; log2 ENþMðjÞÞ (expression data for gene j
in genetically distinct diseased population) have statistically distinguish-
able mean values. We note that we use the log2 of gene expression here.
Indeed, raw gene expression levels measured from microarray fluores-
cence intensity typically have a skewed log-normal distribution resulting
from a multiplicative error during the amplification process. The log
transformation allows to normalize the data distribution and use classical
parametric statistics such as the t-test for analysis. This test is carried out
for all K genes and differentially expressed genes are then ranked in order
of statistical significance (e.g., with increasing p-value less than some
threshold of statistical significance). This approach is well-established and
can be performed using existing bioinformatics tools such as SAM
(Statistical Analysis of Microarrays).19
Because mice from the same strains are isogenic and renewable, the
HMDP offers the possibility to analyze differential gene expression in a
different and unique setting where subjects in the control and diseased
populations have the same genetic background. The control population
consists of one mouse per strain (for N strains) before treatment with a
beta-adrenergic agonist isoproterenol (ISO) inducing cardiac hypertrophy
and heart failure. Since all strains are genetically distinct the subjects in the
control population are genetically distinct and can be labeled as
ðS1; S2; :::; SNÞ (genetically identical control and diseased populations in
the HMDP). Hearts from those subjects before ISO treatment are biopsied
and used for microarray analysis. Biopsy requires sacrificing the animals
that cannot be ISO treated. However, another mouse from the same strain
can be ISO treated and similarly for all N strains. Therefore, the diseased/
treated population is genetically identical to the control population and
has the same degree of genetic diversity.
From the gene expression data alone, we can then perform the standard
SAM type of differential gene expression analysis that consists of deciding
if the gene expression data before log2 E1 jð Þ; log2 E2 jð Þ; ¼ ; log2 EN jð Þð Þ
(expression data for gene j in control strains) and after
log2 E
0
1 jð Þ; log2 E02 jð Þ; ¼ ; log2 E0N jð Þ
 
(expression data for gene j in
genetically identical treated strains) treatment have statistically distin-
guishable mean values, where Ei jð Þ and E0i jð Þ are the expression levels of
gene j for the isogenic subjects Si before (in control) and after ISO
treatment, respectively. To do so, SAM uses a statistics based on the ratio
of change in gene expression to standard deviation in the data for that
gene, yielding the “relative difference”:19
d jð Þ ¼ μ
0
j  μj
s jð Þ þ s0
(3)
where μj and μ
0
j are defined as the average levels of expression for gene j
in control and ISO treatment, respectively, and the denominator s jð Þ þ s0 is
the gene expression scatter as defined in.19 Genes that show a difference
of average expression levels across both conditions that is significantly
larger than their condition-specific scatters are selected and referred to as
SAM genes.
One can also perform an entirely different type of differential gene
expression analysis owing to the fact that, in addition to control and
treated subjects belonging to the same strain having the same genetic
background, the change of heart mass in response to ISO, i.e., the ratio
m0i=mi of total heart mass before (mi) and after ISO treatment (m
0
i ) for strain
i, can be measured for all strains ði ¼ 1; 2; :::;NÞ to assess the degree of
hypertrophy among different strains. This ratio is calculated by measuring
total heart mass for several mice from the same strain before and after ISO
treatment and averaging measured values before and after ISO treatment
prior to taking their ratio. Importantly, values of m0i=mi range continuously
from about 1 (no change of heart mass) to 2 (two-fold change of heart
mass) among strains. Differential gene expression can then be examined
by asking whether a given gene j contributes to the severity of cardiac
hypertrophy. This can be readily done by calculating the coefficient of
correlation .. (e.g., Pearson or Spearman) between the strain-specific fold
change of expression of gene j in response to ISO treatment among
different strains Fj ¼ log2 E
0
1 jð Þ
E1 jð Þ ; log2
E02 jð Þ
E2 jð Þ ; ¼ ; log2
E0N jð Þ
EN jð Þ
 
and the strain-
specific change of heart mass among different strains
Fm ¼ log2 m
0
1
m1
; log2
m02
m2
; ¼ ; log2
m0N
mN
 
. We note that for consistency with
the gene expression we also used the log-ratio of phenotypic change. In
our case, we use the Pearson correlation and compute:
Cj ¼ hFjFmi  hFjihFmi
σFjσFm
(4)
where σ denotes the standard deviation and 〈 〉 the average. Using that
language, we note that the relative difference used for SAM genes can be
rewritten as:
d jð Þ ¼ hFji
s jð Þ þ s0 (5)
This readily shows that SAM genes do not consider the strength of
phenotypic change, but rely on the average gene expression change hFji,
while FC genes reflect how gene expression change affects phenotype
change through the interaction term hFjFmi: Clearly, this correlation
coefficient cannot be calculated in the setting of traditional clinical studies
since the fold change of gene expression or heart mass of subjects with
different genetic background is meaningless. Calculating this correlation
would require to use a population of identical twins in which one twin for
each pair of twins is a heart donor and the other twin is a late stage HF
patient, and donor and explanted hearts could be biopsied.
The HMDP provides the experimental tool to carry out this identical
twins experiment to measure expression data and trait (heart mass) for the
same genetic background under different conditions (before and after ISO
treatment). The correlation coefficients Cj can be positive or negative and
the magnitude of Cj can be used to identify genes and classify them in
order of statistical significance assessed by comparing Cj values computed
with actual data to those computed with a randomized data set (e.g., a set
obtained by permuting the strain labels). We refer to genes identified by
this method as FC genes to reflect the fact that they are obtained by
correlating the individual fold-change of gene expression for all strains (Fj)
with the individual fold-change of heart mass for all strains (Fm).
In this conceptual “identical twin” experiment, only two mice per strain
are used for microarray data analysis in 90% of the strains (one control
mouse and one treated mouse). This experimental limitation stems from
the large number of hearts (over 200) that need to be biopsied and
analyzed for gene expression. However, since mice of a given strain are
renewable, the HMPD offers the possibility to use triplets, quadruplets, and
higher multiples of isogenic subjects for experimentation. This feature was
used to measure gene expression in replicates (e.g., two hearts in control
or two hearts after ISO treatment) to test for replicability in ~10% of the
strains. The results of this replicability analysis shows that genetics play a
dominant role in controlling gene expression and that using two mice per
strain (on in the control group and one in the treated group) is sufficient to
identify FC genes. This conclusion is further supported by the fact that,
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remarkably, the FC genes turn out to be for the most part completely
different than the traditional SAM genes, and causally related to
hypertrophy as assessed by further analysis of pathway enrichment and
direct experimental validation of the role of one FC gene.
Pre-filtering of the data
In order to reduce false positive predictions and computational time, we
first filtered the 25,697 genes expression data. Instead of setting an
arbitrary cutoff based on the level of expression as is commonly done, we
decided to use a network approach that is consistent with the correlation-
based methods used in this study. The idea is that the different genotypic
backgrounds across strains lead to global gene expression modulation,
thus creating correlation between expressed genes. Genes not associated
with the core of varying genes should be the ones that carry too much
experimental noise due to low expression or systematic biases.
We first computed the absolute Pearson correlation of gene expression
fold-change between all pairs of genes. This creates a complete weighted
network containing all genes. We then reasoned that genes for which
expression is noisy because of low expression or experimental artifacts
should have a low association to the other genes. We therefore looked at
the size of the Largest Connected Component (LCC) of the network when
hard-thresholding with several correlation cutoffs (figure S1a). We
observed a fast decrease of the LCC size at low thresholds of 0.35–0.45,
followed by milder steady decrease. The derivative of this curve is
presented in figure S1b, showing a strong initial trough corresponding to
noisy “satellite” nodes being cut from the LCC, followed by stabilization.
We chose a cutoff of 0.5 corresponding to that stabilization plateau and
kept the 11,279 genes in the LCC. The effect of this filter is made clear by
looking at a selection of functional genes linked to the electromechanical
coupling in heart cells (figure S1c). The rejected genes (gray bars) have
either low expression (e.g., Calm4, Kcnd3) or display systematic saturation
effects inherent to the microarray assay, which results in noisy correlations
(e.g., Tnnc1, Atp2a2). More generally, we show in Fig S2 that filtered out
genes show a correlation profile with hypertrophy similar to the one
expected at random. In this paper, we use these 11,279 genes as input to
the different methods.
Computation of randomized correlations
To compute the expected correlations of Fig. 2a, we first shuffle the heart
mass fold-changes among strains. We then compute the correlations
between all genes FCs and this randomized phenotype. We repeat that
step 1000 times. The final histogram is the average over the 1000
randomizations.
Computation of population-wide DEGs
The population-wide DEGs are computed by using Significance Analysis of
Microarray or SAM19 between the post-ISO and the pre-ISO expression
data. Using a False Discovery Rate of 1e-3, we find 2538 significant DEGs.
Conversion from mouse symbols to human entrez IDs
In order to compute pathway and disease genes enrichment, we first
needed to compute a table converting mouse gene symbols to human
entrez IDs. We used UCSC genome browser mm9.kgXref, mm9.hgBlastTab
and hg19.kgXref conversion tables available on the mySQL host genome-
mysql.cse.ucsc.edu. The kgXref tables were used for conversion between
symbols and entrez IDs while the Blast table was used to get the human
orthologs of mouse genes.
HuGE database
Disease genes were taken from the HuGE database of published GWAS
genes,52 with a total of 2711 diseases. HF related diseases were filtered out
using keywords “heart,” “cardi,” “hypert,” “aort,” “fibro.”
Pathways
Pathways were taken from MSigDB v3.153 and Wikipathways,54 with
a total of 8690 sets of genes. A group of 106 genes corresponding to
a previously published CHSN20 was added under the name
“SAUCERMAN_cardiac_hypertrophy_pathway.”
TF enrichment
The cytoscape plugin iRegulon30 was used to predict putative upstream TF
regulating the studied sets of genes. Default parameters were used: 9713
PWMs scanning 20 kb centered around TSS.
Computation of statistics
All statistics (correlations, t-test, Wilcoxon test, hypergeometric test) were
computed using R. Hierarchical clustering was performed using default
parameters of the R hclust function. Z scores correspond to the number of
standard deviations a given observation is away from the mean of the null
(random) distribution and are computed as follow:
Z ¼ x  <X>
< X  <X>ð Þ2> (6)
where x is the observed value, X is a set of random predictions, and < . >
denotes the average.
Cell Culture and Treatments
Right ventricular myocytes were isolated and cultured, as reported55 using
2–4 day old rats. Myocytes and fibroblasts were separated with Percoll
density gradient. For knockdown experiments cells were transfected with
Hes1 siRNA using lipofectamine RNAimax (life technologies).
RNA Isolation and qPCR
RNA isolation from cells was performed using Qiazol lysis reagent. cDNA
synthesis was performed using the High Capacity Reverse Transcription
cDNA Kit (Life Technologies). qPCR was performed using the LightCycler
480 (Roche). The number of replicates per condition is shown in
Supplementary Table S2, with values ranging from 6 to 9.
Quantification of cardiomyocyte cell cross-sectional area
Quantification of cardiomyocyte cell cross-sectional area was done
following transfection with either control or Hes1 siRNA and a 48 h
treatment with control or isoproterenol or phenylepherine containing
media. Images were taken on a Nikon Eclipse TE2000-U microscope.
Images were analyzed using the Nikon Imagine System (NIS). A total of 150
cells were used to compute the SEM.
Code availability
Source codes are available for the community: https://github.com/
msantolini/FC.
Data availability
Microarray data may be accessed at the Gene Expression Omnibus
using accession ID: GSE48760. All phenotypic and expression data
may also be accessed at https://systems.genetics.ucla.edu/data/
hmdp_hypertrophy_heart_failure
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